Cerebellar ataxia pharma news - Ataxia UK

Cerebellar ataxia pharma news

Alterity Therapeutics presents data on the potential of ATH434 to treat FA

The biotechnology company Alterity Therapeutics presented data from their lead Friedreich’s ataxia (FA) drug candidate ATH434 at the 2024 US World Orphan Drug Congress.  In FA, a genetic change in […]

Alterity Therapeutics presents data on the potential of ATH434 to treat FA Read More »

Reflections on the Ataxia UK Annual Conference 2023

On Friday 20th and Saturday 21st October 2023, Ataxia UK held their first ever hybrid in-person and virtual annual conference for families affected by ataxia. The conference, which took place

Reflections on the Ataxia UK Annual Conference 2023 Read More »

US FDA and European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia 

Spinocerebellar ataxias (SCAs) are a group of rare, progressive hereditary genetic disorders that affects the cerebellum, brain stem and spinal cord. Currently, more than 30 types of SCAs have been identified. SCAs are caused by genetic mutations,

US FDA and European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia  Read More »

New Ataxia Consortium created to accelerate the development of treatments for the Ataxias

Ataxia UK, along with Ataxia Global Initiative and National Ataxia Foundation, recently partnered with Critical Path Institute (C-Path) for the launch of their Critical Path to Therapeutics for the Ataxias

New Ataxia Consortium created to accelerate the development of treatments for the Ataxias Read More »

Donate Now
Scroll to Top